

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 March 2002 (28.03.2002)

PCT

(10) International Publication Number
WO 02/24174 A2

- (51) International Patent Classification⁷: **A61K 9/50**
- (21) International Application Number: **PCT/BE01/00164**
- (22) International Filing Date:
21 September 2001 (21.09.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PCT/BE00/00112
22 September 2000 (22.09.2000) **BE**
- (71) Applicant (for all designated States except US): **GALE-PHAR M/F** [BE/BE]; Rue du Parc Industriel 39, B-6900 Marche-en-Famenne (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **VANDEBIST, Francis** [BE/BE]; Avenue des Jardinets 18, B-1170 Bruxelles (BE). **SERENO, Antonio** [BE/BE]; Passiewijk 21, B-1820 Melsbroek (BE). **BAUDIER, Philippe** [FR/BE]; Rue Engeland 338, B-1180 Uccle (BE).
- (74) Agents: **POWIS DE TENBOSSCHE, Roland** et al.; Cabinet Bede S.A., Place de l'Alma 3, B-1200 Brussels (BE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
 - as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designation US
 - of inventorship (Rule 4.17(iv)) for US only
- Published:**
- without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **SUSTAINED RELEASE COMPOSITION CONTAINING CLARITHROMYCIN**

(57) Abstract: A pharmaceutical oral sustained release composition of clarithromycin containing coated pellets comprising each a core containing clarithromycin and a sustained release coating surrounding the core, in which the sustained release coating comprises at least a water insoluble polymer which is substantially pH independent.

WO 02/24174 A2

SUSTAINED RELEASE COMPOSITION CONTAINING
CLARITHROMYCIN

5

ABSTRACT

Disclosed is a method of treating infection including a sustained release
10 oral form of CLARITHROMYCIN constituted by coated pellets and allowing
a once a day administration of the drug.

BACKGROUND OF THE INVENTION

15 Clarithromycin is a semisynthetic macrolide antibiotic derived from
erythromycin. Clarithromycin is primarily bacteriostatic, it exerts its
antimicrobial effect by the inhibition of protein synthesis on bacterial
ribosomes. Clarithromycin is active against the major pathogens
responsible for respiratory tract infections in immunocompetent patients,
20 namely Chlamydia pneumoniae, Mycoplasma pneumoniae, Staphylococcus
aureus, Streptococcus pyogenes, Moraxella catarrhalis, Streptococcus
pneumoniae, Haemophilus influenzae. Clarithromycin is also active against
and Helicobacter pylori.

25 Clarithromycin is rapidly absorbed and its availability after an oral
dose of 250 mg is approximately 55 %. This is probably due to the
first-pass metabolism, which produces, in particular, the 14-hydroxy
active metabolite. It has been shown that the maximal serum
concentration following oral administration are dose dependent and
30 the time to achieve peak blood concentrations is about 2 hours.

There is an effect of food on the bioavailability of clarithromycin and 14- hydroxy-clarithromycin. The food intake immediately before administration increases the bioavailability by a mean of 25%. Such an increase can be considered of little clinical significance with the dosage regimen of 250 and 500 mg twice daily.

Macrolides antibiotics are lipid soluble and extensively distributed both in body fluids and tissues. Clarithromycin also achieves tissue concentrations markedly higher than circulating levels, due to its wide distribution. This aspect is relevant for clinical activity.

Clinical trials in adults have shown similar efficacy for clarithromycin and other antibacterial drugs in the treatment of community-acquired pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis. Comparators agents included the β -lactam agents anpicillin, amoxicillin with or without clavulanic acid, penicillin V, some Cephalosporins (cefactor, cefuroxime, ...) and the other macrolides erythromycin, roxithromycin, azithromycin.

The most usual way of oral administration of clarithromycin to the adults is an immediate release tablet to be taken twice daily.

A modified release formulation of clarithromycin has been developed to allow administration of the drug once daily. This formulation delivers the same peak and trough concentrations of the parent drug and metabolite and reaches equivalent AUC values to those seen with the twice daily immediate-release formulation in the 24 hours after administration. The elimination half life of clarithromycin and its 14-hydroxymetabolite are unaltered by the formulation although peak plasma concentrations are delayed with the once-daily dosage form.

Some developments trials have been made to obtain a sustained-release of clarithromycin after oral administration, for instance :

- Patent 6,010,718 describes a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces significantly lower C_{max} in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
- Patent 5,705,190 describes a controlled release, oral, solid, pharmaceutical composition for a reduced daily dosage regimen, where the therapeutic ingredient is a poorly soluble basic drug. The formulation comprises the use of a water-soluble alginate salt, a complex salt of alginic acid and an organic carboxylic acid in admixture with the therapeutic drug. A particular embodiment comprising a once a day dosage form for clarithromycin is also described.
- Patent 5,051,262 describes an invention which specifically relates to processes for preparing delayed action galenic forms. The process is characterized in that the application solutions of excipients, coatings and active constituents are adjusted to a desired pH. The independence of the rate of dissolution of a controlled release or sustained action oral pharmaceutical form is increased by admixing a pH adjusting agent with every application solution of medicament, excipient or coating, throughout the course of formulation of the pharmaceutical form.

- Patent WO 98/47493 describes a pharmaceutical formulation which is provided in powder form by spray-drying to form a polymeric coated core element which coating both masks the taste of the active ingredient present in the core and provide sustained release properties.

5

BRIEF DESCRIPTION OF THE INVENTION

The present invention relates to a sustained release form of clarithromycin consisting in coated pellets, whereby an once daily administration of the drug is possible.

10

The pharmaceutical oral sustained release composition of clarithromycin of the invention contains clarithromycin coated pellets comprising each a core containing clarithromycin and a sustained release coating surrounding the core, in which the sustained release coating comprises at least a water insoluble polymer which is substantially pH independent at least for a pH range comprised between 2 and 7, advantageously for a pH range from about 2 to 7.5, preferably from 1.5 to 8, most preferably from about 1 to 8. A water insoluble polymer which is substantially independent at least at pH comprised between 2 and 7.5 is a polymer allowing substantially the same rate of passage of clarithromycin in said pH range. The core of the clarithromycin containing pellets contains for example more than 20% by weight, but preferably at least 50% by weight of clarithromycin.

15

20

The core of the clarithromycin containing pellets is advantageously manufactured using the process of extrusion-spheronization.

25

The water insoluble polymer which is substantially pH independent is advantageously selected from the group consisting of acrylic polymers, methacrylic polymers, acrylic copolymers, methacrylic copolymers, acrylic-methacrylic copolymers, cellulosic derivatives, and mixtures thereof.

30

In a preferred embodiment, the water insoluble polymer is an ethyl acrylate and methyl methacrylate neutral copolymer. According to another preferred embodiment, the water insoluble polymer is a cellulosic derivative.

The sustained release coating contains for example from 1 to 50% by weight, but preferably from 5 to 20% by weight of water insoluble polymer which is substantially pH independent. For example, the sustained release coating contains from 5 to 20% by weight of water insoluble acrylic polymer or copolymer or cellulosic derivative which is substantially pH independent.

The clarithromycin containing core is coated with an amount of the sustained release coating corresponding from 1 to 50%, preferably from 6% to 20% of the weight of the clarithromycin containing core. The clarithromycin containing core contains advantageously from 5 to 50% by weight of microcrystalline cellulose and/or from 0.5% to 5% by weight of polyvinylpyrrolidone and/or from 2 and 20% of one or more organic acids. According to a preferred embodiment, the clarithromycin containing core contains microcrystalline cellulose, one or more citric acid and possibly, but preferably, polyvinylpyrrolidone

The sustained release coating has advantageously a thickness between about 30 and 200 μm , advantageously between 30 and 150 μm , for example about 50 μm , about 75 μm , about 100 μm , about 150 μm . According to an advantageous embodiment, the thickness of the sustained release coating is substantially constant. For example the thickness varies essentially in a range of -25% to $+25\%$ with respect to the average thickness, advantageously in a range of -15% to $+15\%$ with respect to the average thickness, preferably in a range of -10% to $+10\%$ with respect to the average thickness.

The pellets have preferably a size between 0.5 and 2.0 mm.

The invention relates also to a pharmaceutically acceptable capsule containing pellets as described here above in the composition of the invention.

The pharmaceutical capsule is for example a soft gelatine capsule, but preferably a hard gelatine capsule.

The pharmaceutical capsule of the invention contains advantageously from 100 to 500 mg of clarithromycin in the form of pellets of the invention.

The pharmaceutical capsule contains preferably a sufficient amount of clarithromycin coated pellets of the invention for having an effective antiinfective effect when administering once daily the patient.

5 With compositions of the invention and capsules of the invention, it is possible to ensure a low maximal concentration in order to decrease the frequency of side effects associated with the intake of clarithromycin.

With compositions of the invention and capsules of the invention, it is possible to ensure a decrease of the intra- and intersubjects variability of
10 the plasma concentration after an oral intake of clarithromycin pellets.

DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows the Influence of the amount of film coating on the in vitro
15 dissolution rate of clarithromycin (n=6 vessels/ test) ;

FIGURE 2 shows a mean pharmacokinetic profile after a multiple dose of 500 mg clarithromycin pellets administered once daily (n=8 subjects).

DESCRIPTION OF PREFERRED EMBODIMENTS

20

Pellets are spheres of varying diameter depending on the application and the wish of the producer. Most often in the pharmaceutical industry the size of the pellets is 0.5-2.0 mm.

Pellets as a drug delivery system offer not only therapeutical advantages
25 such as less irritation of the gastro-intestinal tract, a lowered risk of side effects due to dose dumping and bioavailability less dependent on the food intake but also technological advantages, for example, better flow properties, less friable dosage form, narrow particle size distribution, ease of coating and uniform packing.

30 The reproducibility of the drug blood levels is an additional advantage to the use of a pellet formulation. Pellets are commonly filled into hard gelatine capsules, but can also be compressed to tablets.

Although pellets can be produced in different ways (spraying a solution or suspension onto an inert core, building the pellet layer after layer, spray-drying a solution or a suspension of the drug forming pellets due to the evaporation of fluid phase,...), the most popular method of manufacturing is by the extrusion-spheronisation technique.

This process involves at least five steps : blending-preparation of the net mass (granulation), shaping the net mass into cylinders (extrusion), breaking up the extrudate and rounding of the particles into spheres (spheronisation) and finally drying of the pellets.

It has been found that by using a sustained release coating containing a water insoluble polymer, which is substantially pH independent, that the dissolution rate of clarithromycin could be controlled, at pH below 5 (where the water solubility of clarithromycin is good and quite constant), as well as at higher pH , such as at pH comprised between 5 and 7 (the solubility of clarithromycin decreases dramatically at pH greater than 5 and becomes quasi nil at pH=8). The sustained release coating of the invention controls therefore the release of clarithromycin in the small intestine where the pH is between 5.5 and 7.0. Furthermore, at acidic pH (1.4), the stability of clarithromycin is not optimal. Indeed, the half-life of decomposition of clarithromycin is of 17 minutes at pH = 1.4.

The core pellets of the invention contain preferably more than 50% (w/w) of clarithromycin. The excipients used to allow the manufacture of the pellets include but one restricted to : microcrystalline cellulose, polyvinylpyrrolidose, hypromellose, sucrose stearate, citric acid, stearic acid, lactose and other mono- or disaccharides. In particular, it should be ensured that the excipients used always guarantee an optimal dissolution of clarithromycin.

The granulation is done using a hydro ethanolic solution in which the ratio between water and ethanol varies between 1/50 (w/w) and 1/2 (w/w). This granulating liquid allows to obtain the most suitable mass for the

subsequent extrusion-spheronisation process. Indeed, the use of water alone as granulating liquid provokes the formation of a mass too sticky to allow a good extrusion-spheronisation process.

5 To allow a good extrusion process, the steps of blending and granulation must be performed in a way that allows to prevent the evaporation of the granulation liquid in order to avoid that the granulate mass becomes too dry to be extruded. The granulation-extrusion steps must be performed in a special apparatus which allows the granulation and extrusion as a
10 continuous step. Indeed, the granulator is equipped with a special output, allowing the extrusion once the mass possess the adequate extrusion properties. The granulating tank is also equipped with an airtight cover to prevent evaporation of the granulating liquid.

15 The coating process of the pellets may be performed, for instance, using the fluid bed coater technology.

To guarantee a continuous release and dissolution of clarithromycin, polymer coating must have properties such as it allows a release of the drug which is independent to the pH. The most suitable polymers for the
20 purpose and which are pharmaceutically acceptable are the family of neutral acrylic derivatives and the water insoluble cellulosic derivatives such as ethylcellulose.

EXAMPLES

25

Some Examples of formulations for the core pellets and the coatings of the pellets are given hereinbelow.

30

Formulations5 **Core pellets**

Ingredients	F1	F2	F3	F4	F5
Clarithromycin	60	72	60	60	60
Microcrystalline cellulose	19	26	34	19	19
Povidone	2	2	---	---	2
Citric acid Trihydrate	14	---	---	---	19
Stearic acid	5	---	---	---	---
Sucrose stearate	---	---	4	---	---
hypromellose	---	---	2	2	---
Lactose	---	---	---	19	---

The pellets or microgranules had a size comprised between 0.5 mm and about 2 mm.

10 **Coatings**

	C1	C2	C3
Polyacrylate dispersion 30 % (Dry residue)	65.6	---	---
Ammonio methacrylate copolymer	---	64.83	---
Ethylcellulose	---	---	64.8
Polysorbate 80	0.15	---	---
Siméthicone emulsion	1.46	1.50	---
Hypromellose	10.93	7.54	---
Talc	14.58	15.07	22.61
Titanium dioxide	7.28	7.54	7.54
Triacetin	---	---	5.03
Triethyl citrate	---	3.52	---

The coatings C1,C2,C3 can be applied on anyone of the core pellets F1 to F5.

5 The thickness of the coating on the pellets was about 30-200 μm . Other thickness are possible and the thickness can be adapted in accordance to the requirement.

The dissolution test is usually the most appropriate analytical tool to assess the quality of the oral formulations and especially of sustained release oral formulations.

10

The conditions used for assessing the dissolution rate of clarithromycin are the following :

- Paddle Apparatus (EP, 3rd edition, 2.9.3, figure 1)
- 15 □ pH 5.0 (phosphate buffer)
- Rotation speed of the paddles : 100 rpm
- Detection : HPLC (UV detection) (wavelength 286 nm)
- Volume of dissolution liquid : 900 ml

20 The figure 1 hereinbelow shows the influence of the amount of film coating on the dissolution rate of clarithromycin

FIGURE 1 shows the Influence of the amount of film coating on the in vitro dissolution rate of clarithromycin (n=6 vessels/ test).

25 Logically, the dissolution rate of clarithromycin decreases when the amount of film coating increases. As it can be seen from said figure, the % of dissolved clarithromycin was about 80% after about 5 minutes when using an amount of coating corresponding to 10% of the weight of the core, while said % of dissolved clarithromycin after 5 minutes was respectively about
30 40% and about 20% when using respectively an amount of coating corresponding to 12% and 14% of the weight of the core.

An in vivo, multiple dose pharmacokinetic study has been performed on 8 healthy volunteers to assess the bioavailability of the compositions relative to the present invention.

- 5 The mean pharmacokinetic profile obtained is given in figure 2 [Mean pharmacokinetic profile after a multiple dose of 500 mg clarithromycin pellets administered once daily (n=8 subjects)]. The tested patients received a hard gelatine capsule containing coated pellets corresponding to 500mg clarithromycin.

10

As it can be seen from figure 2, by using the composition of the invention it is possible to provide a sustained release once a day formulation of clarithromycin. The said formulation being efficient to treat or prevent infections and presenting a more favourable profile of side effects than the existing immediate release tablet and than the existing sustained release
15 tablets.

This safer profile is due to a lower C_{max} of clarithromycin than the references after a multiple dose administration of clarithromycin. For
20 comparison, the C_{max} obtained after a multiple dose administration of the the reference BICLAR 250 mg is of 1.0 $\mu\text{g/ml}$. For BICLAR 500 mg, the C_{max} obtained after a multiple dose administration is of 2.7 $\mu\text{g/ml}$. The formulation relative to the invention clearly provides lower C_{max} than the immediate release formulations of clarithromycin. Moreover, it is clear from
25 figure 2, that release of clarithromycin allows to obtain effective plasmatic concentration of clarithromycin 24 hours after the intake.

By using the composition of the invention, it is also possible to obtain lower intra and inter individual variability than the commercialized forms of
30 clarithromycin. The variability obtained in the pharmacokinetic study described in figure 2 is low.

CLAIMS

- 5 1. A pharmaceutical oral sustained release composition of clarithromycin containing coated pellets comprising each a core containing clarithromycin and a sustained release coating surrounding the core, in which the sustained release coating comprises at least a water insoluble polymer which is substantially pH independent at least for a pH range from 2 to 7.
- 10 2. The pharmaceutical composition of claim 1, in which the core of the clarithromycin containing pellets contains at least 50% by weight of clarithromycin.
3. The pharmaceutical composition of claim 1, in which the core of the clarithromycin containing pellets is manufactured using the process
15 of extrusion-spheronization.
4. The pharmaceutical composition of claim 1, wherein the water insoluble polymer which is substantially pH independent is selected from the group consisting of acrylic polymers, methacrylic polymers, acrylic copolymers, methacrylic copolymers, acrylic-methacrylic
20 copolymers, cellulosic derivatives, and mixtures thereof.
5. The pharmaceutical composition of claim 1, wherein the water insoluble polymer is an ethyl acrylate and methyl methacrylate neutral copolymer.
6. The pharmaceutical composition of claim 1, in which the sustained
25 release coating contains from 5 to 20% by weight of water insoluble polymer which is substantially pH independent.
7. The pharmaceutical composition of claim 1, in which the sustained release coating contains from 5 to 20% by weight of water insoluble acrylic polymer or copolymer which is substantially pH independent.
- 30 8. The pharmaceutical composition of claim 1, wherein the clarithromycin containing core is coated with an amount of the

sustained release coating corresponding from 6% to 20% of the weight of the clarithromycin containing core.

9. The pharmaceutical composition of claim 1, wherein the core of the clarithromycin containing pellets contains between 5 and 50% by weight of microcrystalline cellulose
10. The pharmaceutical composition of claim 1, wherein the core of the clarithromycin containing pellets contains between 0.5% and 5% by weight of polyvinylpyrrolidone
11. The pharmaceutical composition of claim 1, wherein the core of the clarithromycin containing pellets contains between 2 and 20% of one or more organic acids.
12. The pharmaceutical composition of claim 1, wherein the sustained release coating has a thickness between 30 and 200 μm
13. The pharmaceutical composition of claim 1, wherein the water insoluble polymer is a cellulosic derivative.
14. The pharmaceutical composition of claim 1, wherein the pellets have a size between 0.5 and 2.0 mm.
15. The pharmaceutical composition of claim 1, which contains an effective amount of clarithromycin for ensuring, when administering the composition once daily, an effective antiinfective effect during one day.
16. A pharmaceutically acceptable capsule containing pellets of anyone of the claims 1 to 15.
17. The pharmaceutical capsule of claim 16, where the capsule is a hard gelatine capsule.
18. The pharmaceutical capsule of claim 16, which contains from 100 to 500 mg of clarithromycin in the form of pellets of anyone of the claims 1 to 14.

1/1




Figure 1




Figure 2

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 March 2002 (28.03.2002)

PCT

(10) International Publication Number
WO 02/024174 A3

(51) International Patent Classification⁷: **A61K 9/50**,
31/7048

(21) International Application Number: PCT/BE01/00164

(22) International Filing Date:
21 September 2001 (21.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/BE00/00112
22 September 2000 (22.09.2000) BE

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designation US
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
26 September 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for all designated States except US*): **GALE-PHAR M/F** [BE/BE]; Rue du Parc Industriel 39, B-6900 Marche-en-Famenne (BE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **VANDEBIST, Francis** [BE/BE]; Alsebergsesteenweg 1116, B-1650 Beersel (BE). **SERENO, Antonio** [BE/BE]; Passiewijk 21, B-1820 Melsbroek (BE). **BAUDIER, Philippe** [FR/BE]; Rue Engeland 338, B-1180 Uccle (BE).

(74) Agents: **POWIS DE TENBOSSCHE, Roland** et al.; Cabinet Bede S.A., Place de l'Alma 3, B-1200 Brussels (BE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

(54) Title: SUSTAINED RELEASE COMPOSITION CONTAINING CLARITHROMYCIN

(57) Abstract: A pharmaceutical oral sustained release composition of clarithromycin containing coated pellets comprising each a core containing clarithromycin and a sustained release coating surrounding the core, in which the sustained release coating comprises at least a water insoluble polymer which is substantially pH independent.

WO 02/024174 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/BE 01/00164

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/50 A61K31/7048

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 47493 A (FAULDING F H & CO LTD ;PITMAN IAN HAMILTON (AU)) 29 October 1998 (1998-10-29) cited in the application	1,2,4-7, 12-15
A	page 1, line 18 - line 27 page 2, line 4 - line 26 page 2, line 30 -page 3, line 14 page 6, line 8 - line 25 page 7, line 16 - line 17 page 11, line 23 -page 12, line 2; claims 1-6,9; example 4	16-18
X	EP 0 293 885 A (ABBOTT LAB) 7 December 1988 (1988-12-07)	1,2,4, 13-15 16-18
A	page 2, column 4, line 41 - line 44 page 5, line 16 - line 30; claims 1,2	
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

12 July 2002

Date of mailing of the international search report

24/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Marttin, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/BE 01/00164

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 22319 A (ABBOTT LAB) 24 August 1995 (1995-08-24) page 1, line 9 - line 34 page 4, line 9 - line 10 page 5, line 11 - last line page 6, line 14 -page 7, line 7; claims; example 1 ---	1-18
P,X	WO 01 35930 A (KHAR ROOP K ;KUMAR MANOJ (IN); MUKHERJI GOUR (IN); SEN HIMADRI (IN) 25 May 2001 (2001-05-25) page 5, line 1 - line 15 page 6, line 14 - line 21 page 7, line 10 -page 8, line 4; claims 1,5,10,12-14; examples 3,4 ---	1,2,4,8, 13,14, 16,17
P,X	WO 01 62195 A (ADVANCED PHARMA INC) 30 August 2001 (2001-08-30) page 16, paragraph 2 page 21, paragraph 2; claims 1,2,4,7,8; examples 36-39,102-10 -----	1-5,13, 15-17

INTERNATIONAL SEARCH REPORT

International Application No

PCT/BE 01/00164

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9847493	A	29-10-1998	AU 7015598 A	13-11-1998
			WO 9847493 A1	29-10-1998
			CA 2252773 A1	29-10-1998
			EP 0935460 A1	18-08-1999
EP 0293885	A	07-12-1988	US 4808411 A	28-02-1989
			CA 1328609 A1	19-04-1994
			DE 3884461 D1	04-11-1993
			DE 3884461 T2	03-03-1994
			EP 0293885 A2	07-12-1988
			ES 2059437 T3	16-11-1994
			JP 2779167 B2	23-07-1998
			JP 63310832 A	19-12-1988
WO 9522319	A	24-08-1995	EP 0744941 A1	04-12-1996
			JP 9509176 T	16-09-1997
			WO 9522319 A1	24-08-1995
			US 6063313 A	16-05-2000
WO 0135930	A	25-05-2001	WO 0135930 A1	25-05-2001
			AU 1169601 A	30-05-2001
WO 0162195	A	30-08-2001	AU 3984101 A	03-09-2001
			WO 0162195 A1	30-08-2001
			US 2002004499 A1	10-01-2002